Legend Biotech Corporation (LEGN)
NASDAQ: LEGN · Real-Time Price · USD
39.59
+0.15 (0.38%)
At close: Jul 15, 2025, 4:00 PM
39.59
0.00 (0.00%)
Pre-market: Jul 16, 2025, 4:17 AM EDT
Legend Biotech Stock Forecast
Stock Price Forecast
The 11 analysts that cover Legend Biotech stock have a consensus rating of "Strong Buy" and an average price target of $74.6, which forecasts a 88.43% increase in the stock price over the next year. The lowest target is $54 and the highest is $86.
Price Target: $74.6 (+88.43%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Legend Biotech stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 5 | 5 | 5 | 4 |
| Buy | 7 | 6 | 7 | 7 | 7 | 6 |
| Hold | 0 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 13 | 13 | 13 | 13 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Buy Maintains $80 → $81 | Buy | Maintains | $80 → $81 | +104.60% | Jul 10, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $75 | Strong Buy | Reiterates | $75 | +89.44% | Jul 8, 2025 |
| UBS | UBS | Strong Buy Maintains $60 → $54 | Strong Buy | Maintains | $60 → $54 | +36.40% | Jul 2, 2025 |
| Truist Securities | Truist Securities | Strong Buy Maintains $88 → $71 | Strong Buy | Maintains | $88 → $71 | +79.34% | May 14, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $55 | Buy | Reiterates | $55 | +38.92% | May 14, 2025 |
Financial Forecast
Revenue This Year
1.04B
from 627.24M
Increased by 65.33%
Revenue Next Year
1.60B
from 1.04B
Increased by 54.68%
EPS This Year
-0.57
from -0.97
EPS Next Year
0.59
from -0.57
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.2B | 1.9B | 2.9B | ||
| Avg | 1.0B | 1.6B | 2.2B | ||
| Low | 906.6M | 1.2B | 1.7B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 94.3% | 87.0% | 78.9% | ||
| Avg | 65.3% | 54.7% | 35.5% | ||
| Low | 44.5% | 15.6% | 8.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.22 | 1.40 | 1.35 | ||
| Avg | -0.57 | 0.59 | 1.05 | ||
| Low | -1.10 | 0.12 | 0.89 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 128.5% | ||
| Avg | - | - | 77.8% | ||
| Low | - | - | 50.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.